Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Launches Generic Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb, Sanofi-Aventis may seek preliminary injunction against Apotex.

You may also be interested in...



Plavix Takes A Final Bow, But Will It Go Gracefully?

Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.

Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix

Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.

Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix

Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel